Skip to Main content Skip to Navigation
Journal articles

Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma Final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network

Document type :
Journal articles
Complete list of metadata

https://hal-univ-rennes1.archives-ouvertes.fr/hal-02182035
Contributor : Accord Elsevier CCSD Connect in order to contact the contributor
Submitted on : Monday, October 25, 2021 - 1:51:39 PM
Last modification on : Friday, August 5, 2022 - 3:37:03 AM
Long-term archiving on: : Wednesday, January 26, 2022 - 8:21:18 PM

File

S0959804919303508.pdf
Files produced by the author(s)

Licence


Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

Identifiers

Citation

C. Soussain, S. Choquet, M. Blonski, D. Leclercq, C. Houillier, et al.. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma Final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network. European Journal of Cancer, Elsevier, 2019, 117, pp.121-130. ⟨10.1016/j.ejca.2019.05.024⟩. ⟨hal-02182035⟩

Share

Metrics

Record views

37

Files downloads

454